Novartis wins FDA approval for Tasigna

Novartis has won FDA approval of Tasigna for patients with chronic myeloid leukemia who are resistant to Gleevec. Patients will be tested for the Philadelphia chromosome. "Tasigna represents an important advance for the small number of patients who are resistant or intolerant to prior therapy," said David Epstein, president and chief executive of Novartis Oncology. "This approval means we can offer physicians a comprehensive treatment approach with effective medicines to treat their Ph+ CML patients."

- see this release from Novartis
- read the report from MarketWatch on the approval

ALSO: Novartis was sued by a U.S. law firm claiming the drug giant withheld adverse research information on Tasigna. Report

Related Articles:
Novartis makes the "Biggest Splash." Report
Lagging sales spur Novartis layoffs. Report
Novartis plots $700M biotech plant. Report
Novartis bankrolls a drug manufacturing revolution. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.